



Editorial

What Do Alpha-1 Antitrypsin Levels Tell Us About Chronic Inflammation in COPD?

¿Qué nos dicen los niveles de alfa-1 antitripsina sobre la inflamación crónica en EPOC?

Paul Ellis, Alice Turner*

Institute of Applied Health Research, University of Birmingham, UK

Alpha 1-antitrypsin, a member of the serine proteinase inhibitor or serpin super family,¹ is a potent inhibitor of neutrophil elastase and other proteases. Patients with serum deficiency of AAT (alpha-1 antitrypsin deficiency; AATD) due to mutations in the SERPINA1 gene locus have early onset panacinar emphysema that typically has a bibasal predominance. It was this observation that led to the protease-antiprotease hypothesis in COPD. AATD is a clinically relevant phenotype of respiratory disease, with specific treatment available in the form of intravenous augmentation therapy which elevates AAT levels closer to normal and reduces progression of emphysema.² Case finding for AATD in symptomatic respiratory patients is recommended by the World Health Organisation and by experts in AATD in Europe,³ consequently measurement of AAT level in clinical practice would usually be done to identify and then manage such patients. A number of genetic polymorphisms can cause AATD, with the normal allele known as M and the most common deficiency alleles being S and Z; individuals with 2 abnormal alleles are at higher risk of developing emphysema and COPD, and those who are MZ heterozygotes have increased risk in the presence of environmental risk factors such as smoking.⁴ Similar to CRP and fibrinogen, AAT is also a positive acute phase protein where hepatic synthesis of AAT is augmented by interleukin 6 (IL-6) in response to tissue inflammation.⁵ It is considered a reliable marker of systemic inflammation although its role in this capacity is less well studied in relation to COPD, where pulmonary inflammation is a definite feature, and systemic inflammation a potential poor prognostic marker.⁶

Janciauskiene et al.⁷ conducted a post hoc analysis of the relationship between serum AAT levels in patients with COPD (defined as post bronchodilator FEV1/FVC ratio <0.7), those with respiratory symptoms and no COPD and healthy participants. Data was collected from the EPI-SCAN study, a multicentre, cross sectional, observational study of the Spanish population with the primary objective of establishing the national prevalence of COPD in indi-

viduals between 40 and 80 years old. Of the 3802 patients enrolled, 837 had a plasma AAT level available and were included in the analysis reported in this journal. Those with COPD and respiratory symptoms had higher adjusted serum levels of AAT compared to control (1.55 g/L, 1.57 g/L and 1.43 g/L respectively). Though these results meet the generally accepted level of statistical significance ($p < 0.001$), the clinical impact of these findings is less clear. The authors plausibly propose that AAT could serve as a surrogate marker of chronic inflammation and as a biomarker for long-term outcomes in COPD. Given the small actual differences in AAT level between groups it seems logical that it could form one part of a composite score with inclusion of other relevant biomarkers, rather than a standalone test, to risk stratify COPD patients and allow targeted therapy. Certainly, inclusion of an AAT level for all patients with a new COPD diagnosis would simultaneously screen for AATD and is therefore a worthwhile area of further scientific exploration. The authors add to data collected from the Copenhagen General Population study which characterised the SERPINA1 genotype and AAT level of 13,405 individuals with and without COPD which found increased inflammatory markers including AAT in smokers and patients with COPD compared with control.⁸

It is worth mentioning that there is significant overlap in serum AAT levels between genotypes for AATD, and variation in level alone is therefore not adequate to diagnose MZ or other intermediate deficiencies,³ in part due to the impact of inflammation at the time of sampling. Simultaneous measurement of CRP is one proposed strategy to recognise falsely elevated AAT level as a result of an acute phase protein response.⁹ Further genotyping could be reserved for those with levels lower than 24.4 $\mu\text{M/L}$ (1.1 g/L) to detect known common deficiencies (SZ, ZZ, etc.) or gene sequencing for those suspected to have rarer variants.¹⁰ The study by Janciauskiene et al.⁷ reported 57 patients with low levels of AAT which may represent an underlying AAT deficiency. Unfortunately, specific patient genotypes were not available in this study which means that we cannot be certain of either AATD prevalence in Spanish patients who have COPD, or of the degree to which systemic inflammation in COPD is masking underlying AATD. For example, an undetected PiZ heterozygote would have significantly lower serum AAT levels compared with a patient homozygous for the

 DOI of original article: <https://doi.org/10.1016/j.arbres.2019.03.001>

* Corresponding author.

 E-mail address: a.m.turner@bham.ac.uk (A. Turner).

M allele. In addition, patients in the study were not assessed for symptoms of a pulmonary exacerbation at the time of biological sampling. Since AAT is an acute phase protein, AAT could have been falsely elevated in some cases. Both of these scenarios would alter the validity of any of the study conclusions and is a limitation of the study design acknowledged by the authors.

The authors raise an interesting discussion regarding chronic inflammation associated with COPD. It is commonly observed that patients with COPD are multimorbid with increased incidence of disease with similar inflammatory aetiologies. These include cardiovascular disease, osteoporosis, diabetes mellitus and skeletal muscle dysfunction.¹¹ A recent systematic review concluded that patients with stable COPD have raised markers of systemic inflammation including CRP, fibrinogen and WCC with associated increased risk of mortality.¹²

The observation that AAT levels are higher in patients with COPD supports the presence of chronic systemic inflammation. It remains unclear whether inflammation is the result of a primary systemic problem (such as might result from a genetic cause, like AATD), spill over of inflammatory cytokines from the lungs or secondary to co-morbidity observed in COPD (such as inflammation associated with ischaemic heart disease).¹³ Attempts to manage inflammation as a primary pathology in COPD have had varying degrees of success. Early trials of anti-tumour necrosis factor therapy reported no benefit in symptom outcomes¹⁴ despite its effectiveness in the treatment of other inflammatory disease such as rheumatoid arthritis and inflammatory bowel disease. However monoclonal antibodies targeting eosinophilic inflammation have had greater impact.¹⁵ In addition inhaled steroids appear increasingly likely to only benefit patients with relatively high blood eosinophils.¹⁶ This may simply indicate that neutrophilic COPD has a more complex underlying inflammatory phenotype with interaction of multiple cytokines that cannot be addressed by targeting individual molecules. Further trials are needed to explore the usefulness of specific therapies against implicated inflammatory cytokines, to delineate the contribution of AATD to inflammatory pathologies and to elucidate whether serum AAT level is a useful biomarker for chronic inflammation in COPD beyond its role as an indicator of deficiency genotypes.

Funding

No specific funding was received for this article. PRE is supported by a research grant from the Alpha 1 Foundation. AMT has current funding from the ATS Foundation, Alpha 1 Foundation, NIHR, Chiesi, AstraZeneca and CSL Behring

Conflict of interest

Alice Turner research grant received within the last 3 years from Grifols biotherapeutics and CSL Behring

References

1. Lomas DA. 1-Antitrypsin deficiency * 4 molecular pathophysiology. *Thorax*. 2004;59:529–35.
2. Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. *Int J Chron Obstruct Pulmon Dis*. 2017;12:1295–308.
3. Miravittles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. *Eur Resp J*. 2017;50.
4. Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. *Thorax*. 2004;59:843–9.
5. Morgan K, Marsters P, Morley S, van Gent D, Hejazi A, Backx M, et al. Oncostatin M induced alpha1-antitrypsin (AAT) gene expression in Hep G2 cells is mediated by a 3' enhancer. *Biochem J*. 2002;365 Pt 2:555–60.
6. Agusti A, Edwards LD, Rennard SI, Macnee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PLoS ONE*. 2012;7:e37483.
7. Janciauskiene S, DeLuca DS, Barrecheguren M, Welte T, Miravittles M. Serum levels of alpha-1 antitrypsin deficiency and their relationship with COPD in the general Spanish population. *Archivos de Bronconeumologia*. 2020;56:76–83.
8. Thomsen M, Nordestgaard BG, Vestbo J, Lange P. Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. *Lancet Respir Med*. 2013;1:543–50.
9. Sanders CL, Ponte A, Kueppers F. The effects of inflammation on alpha 1 antitrypsin levels in a national screening cohort. *Copd*. 2018;15:10–6.
10. Ferrarotti I, Thun GA, Zorzetto M, Ottaviani S, Imboden M, Schindler C, et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. *Thorax*. 2012;67:669–74.
11. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. *Thorax*. 2010;65:930–6.
12. Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. *Thorax*. 2019;74:439–46.
13. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Lancet Respir Med*. 2015;3:631–9.
14. Barnes PJ. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2007;175:866–7.
15. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. *N Engl J Med*. 2017;377:1613–29.
16. Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil levels as a biomarker in COPD. *Respir Med*. 2018;138:21–31.